Report Cover

Global and China CINV Existing and Pipeline Drugs Market Insights, Forecast to 2026


CINV Existing and Pipeline Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global CINV Existing and Pipeline Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the CINV Existing and Pipeline Drugs market is segmented into
    Aloxi (palonosetron)
    Zofran Generic (ondansetron)
    Kytril Generic (granisetron)
    Emend (aprepitant)
    Akynzeo (netupitant-palonosetron)
    SUSTOL (extended release granisetron injection)
    Rolapitant

Segment by Application, the CINV Existing and Pipeline Drugs market is segmented into
    Hospitals
    Specialty Clinics
    Diagnostic Centers Therapeutics
    Hospital Pharmacies
    Drugstores

Regional and Country-level Analysis
The CINV Existing and Pipeline Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the CINV Existing and Pipeline Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and CINV Existing and Pipeline Drugs Market Share Analysis
CINV Existing and Pipeline Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in CINV Existing and Pipeline Drugs business, the date to enter into the CINV Existing and Pipeline Drugs market, CINV Existing and Pipeline Drugs product introduction, recent developments, etc.
The major vendors covered:
    GlaxoSmithKline
    Helsinn
    Heron Therapeutics
    Merck
    Tesaro
    ...
1 Study Coverage
    1.1 CINV Existing and Pipeline Drugs Product Introduction
    1.2 Market Segments
    1.3 Key CINV Existing and Pipeline Drugs Manufacturers Covered: Ranking by Revenue
    1.4 Market by Type
        1.4.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type
        1.4.2 Aloxi (palonosetron)
        1.4.3 Zofran Generic (ondansetron)
        1.4.4 Kytril Generic (granisetron)
        1.4.5 Emend (aprepitant)
        1.4.6 Akynzeo (netupitant-palonosetron)
        1.4.7 SUSTOL (extended release granisetron injection)
        1.4.8 Rolapitant
    1.5 Market by Application
        1.5.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application
        1.5.2 Hospitals
        1.5.3 Specialty Clinics
        1.5.4 Diagnostic Centers Therapeutics
        1.5.5 Hospital Pharmacies
        1.5.6 Drugstores
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global CINV Existing and Pipeline Drugs Market Size, Estimates and Forecasts
        2.1.1 Global CINV Existing and Pipeline Drugs Revenue 2015-2026
        2.1.2 Global CINV Existing and Pipeline Drugs Sales 2015-2026
    2.2 Global CINV Existing and Pipeline Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    2.3 CINV Existing and Pipeline Drugs Historical Market Size by Region (2015-2020)
        2.3.1 Global CINV Existing and Pipeline Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
        2.3.2 Global CINV Existing and Pipeline Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
    2.4 CINV Existing and Pipeline Drugs Market Estimates and Projections by Region (2021-2026)
        2.4.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Region (2021-2026)
        2.4.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Region (2021-2026)

3 Global CINV Existing and Pipeline Drugs Competitor Landscape by Players
    3.1 Global Top CINV Existing and Pipeline Drugs Sales by Manufacturers
        3.1.1 Global CINV Existing and Pipeline Drugs Sales by Manufacturers (2015-2020)
        3.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2015-2020)
    3.2 Global CINV Existing and Pipeline Drugs Manufacturers by Revenue
        3.2.1 Global CINV Existing and Pipeline Drugs Revenue by Manufacturers (2015-2020)
        3.2.2 Global CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2015-2020)
        3.2.3 Global CINV Existing and Pipeline Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
        3.2.4 Global Top 10 and Top 5 Companies by CINV Existing and Pipeline Drugs Revenue in 2019
        3.2.5 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Global CINV Existing and Pipeline Drugs Price by Manufacturers
    3.4 Global CINV Existing and Pipeline Drugs Manufacturing Base Distribution, Product Types
        3.4.1 CINV Existing and Pipeline Drugs Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers CINV Existing and Pipeline Drugs Product Type
        3.4.3 Date of International Manufacturers Enter into CINV Existing and Pipeline Drugs Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
    4.1 Global CINV Existing and Pipeline Drugs Market Size by Type (2015-2020)
        4.1.1 Global CINV Existing and Pipeline Drugs Sales by Type (2015-2020)
        4.1.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2015-2020)
        4.1.3 CINV Existing and Pipeline Drugs Average Selling Price (ASP) by Type (2015-2026)
    4.2 Global CINV Existing and Pipeline Drugs Market Size Forecast by Type (2021-2026)
        4.2.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2021-2026)
        4.2.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Type (2021-2026)
        4.2.3 CINV Existing and Pipeline Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
    4.3 Global CINV Existing and Pipeline Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
    5.1 Global CINV Existing and Pipeline Drugs Market Size by Application (2015-2020)
        5.1.1 Global CINV Existing and Pipeline Drugs Sales by Application (2015-2020)
        5.1.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2015-2020)
        5.1.3 CINV Existing and Pipeline Drugs Price by Application (2015-2020)
    5.2 CINV Existing and Pipeline Drugs Market Size Forecast by Application (2021-2026)
        5.2.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2021-2026)
        5.2.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Application (2021-2026)
        5.2.3 Global CINV Existing and Pipeline Drugs Price Forecast by Application (2021-2026)

6 China by Players, Type and Application
    6.1 China CINV Existing and Pipeline Drugs Market Size YoY Growth 2015-2026
        6.1.1 China CINV Existing and Pipeline Drugs Sales YoY Growth 2015-2026
        6.1.2 China CINV Existing and Pipeline Drugs Revenue YoY Growth 2015-2026
        6.1.3 China CINV Existing and Pipeline Drugs Market Share in Global Market 2015-2026
    6.2 China CINV Existing and Pipeline Drugs Market Size by Players (International and Local Players)
        6.2.1 China Top CINV Existing and Pipeline Drugs Players by Sales (2015-2020)
        6.2.2 China Top CINV Existing and Pipeline Drugs Players by Revenue (2015-2020)
    6.3 China CINV Existing and Pipeline Drugs Historic Market Review by Type (2015-2020)
        6.3.1 China CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020)
        6.3.2 China CINV Existing and Pipeline Drugs Revenue Market Share by Type (2015-2020)
        6.3.3 China CINV Existing and Pipeline Drugs Price by Type (2015-2020)
    6.4 China CINV Existing and Pipeline Drugs Market Estimates and Forecasts by Type (2021-2026)
        6.4.1 China CINV Existing and Pipeline Drugs Sales Forecast by Type (2021-2026)
        6.4.2 China CINV Existing and Pipeline Drugs Revenue Forecast by Type (2021-2026)
        6.4.3 China CINV Existing and Pipeline Drugs Price Forecast by Type (2021-2026)
    6.5 China CINV Existing and Pipeline Drugs Historic Market Review by Application (2015-2020)
        6.5.1 China CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
        6.5.2 China CINV Existing and Pipeline Drugs Revenue Market Share by Application (2015-2020)
        6.5.3 China CINV Existing and Pipeline Drugs Price by Application (2015-2020)
    6.6 China CINV Existing and Pipeline Drugs Market Estimates and Forecasts by Application (2021-2026)
        6.6.1 China CINV Existing and Pipeline Drugs Sales Forecast by Application (2021-2026)
        6.6.2 China CINV Existing and Pipeline Drugs Revenue Forecast by Application (2021-2026)
        6.6.3 China CINV Existing and Pipeline Drugs Price Forecast by Application (2021-2026)

7 North America
    7.1 North America CINV Existing and Pipeline Drugs Market Size YoY Growth 2015-2026
    7.2 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
        7.2.1 North America CINV Existing and Pipeline Drugs Sales by Country (2015-2020)
        7.2.2 North America CINV Existing and Pipeline Drugs Revenue by Country (2015-2020)
        7.2.3 U.S.
        7.2.4 Canada

8 Europe
    8.1 Europe CINV Existing and Pipeline Drugs Market Size YoY Growth 2015-2026
    8.2 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Country
        8.2.1 Europe CINV Existing and Pipeline Drugs Sales by Country
        8.2.2 Europe CINV Existing and Pipeline Drugs Revenue by Country
        8.2.3 Germany
        8.2.4 France
        8.2.5 U.K.
        8.2.6 Italy
        8.2.7 Russia

9 Asia Pacific
    9.1 Asia Pacific CINV Existing and Pipeline Drugs Market Size YoY Growth 2015-2026
    9.2 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Country
        9.2.1 Asia Pacific CINV Existing and Pipeline Drugs Sales by Region (2015-2020)
        9.2.2 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region
        9.2.3 China
        9.2.4 Japan
        9.2.5 South Korea
        9.2.6 India
        9.2.7 Australia
        9.2.8 Taiwan
        9.2.9 Indonesia
        9.2.10 Thailand
        9.2.11 Malaysia
        9.2.12 Philippines
        9.2.13 Vietnam

10 Latin America
    10.1 Latin America CINV Existing and Pipeline Drugs Market Size YoY Growth 2015-2026
    10.2 Latin America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
        10.2.1 Latin America CINV Existing and Pipeline Drugs Sales by Country
        10.2.2 Latin America CINV Existing and Pipeline Drugs Revenue by Country
        10.2.3 Mexico
        10.2.4 Brazil
        10.2.5 Argentina

11 Middle East and Africa
    11.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size YoY Growth 2015-2026
    11.2 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Country
        11.2.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country
        11.2.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country
        11.2.3 Turkey
        11.2.4 Saudi Arabia
        11.2.5 U.A.E

12 Company Profiles
    12.1 GlaxoSmithKline
        12.1.1 GlaxoSmithKline Corporation Information
        12.1.2 GlaxoSmithKline Description and Business Overview
        12.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
        12.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
        12.1.5 GlaxoSmithKline Recent Development
    12.2 Helsinn
        12.2.1 Helsinn Corporation Information
        12.2.2 Helsinn Description and Business Overview
        12.2.3 Helsinn Sales, Revenue and Gross Margin (2015-2020)
        12.2.4 Helsinn CINV Existing and Pipeline Drugs Products Offered
        12.2.5 Helsinn Recent Development
    12.3 Heron Therapeutics
        12.3.1 Heron Therapeutics Corporation Information
        12.3.2 Heron Therapeutics Description and Business Overview
        12.3.3 Heron Therapeutics Sales, Revenue and Gross Margin (2015-2020)
        12.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Products Offered
        12.3.5 Heron Therapeutics Recent Development
    12.4 Merck
        12.4.1 Merck Corporation Information
        12.4.2 Merck Description and Business Overview
        12.4.3 Merck Sales, Revenue and Gross Margin (2015-2020)
        12.4.4 Merck CINV Existing and Pipeline Drugs Products Offered
        12.4.5 Merck Recent Development
    12.5 Tesaro
        12.5.1 Tesaro Corporation Information
        12.5.2 Tesaro Description and Business Overview
        12.5.3 Tesaro Sales, Revenue and Gross Margin (2015-2020)
        12.5.4 Tesaro CINV Existing and Pipeline Drugs Products Offered
        12.5.5 Tesaro Recent Development
    12.11 GlaxoSmithKline
        12.11.1 GlaxoSmithKline Corporation Information
        12.11.2 GlaxoSmithKline Description and Business Overview
        12.11.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
        12.11.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
        12.11.5 GlaxoSmithKline Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    13.1 Market Opportunities and Drivers
    13.2 Market Challenges
    13.3 Market Risks/Restraints
    13.4 Porter's Five Forces Analysis
    13.5 Primary Interviews with Key CINV Existing and Pipeline Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
    14.1 Value Chain Analysis
    14.2 CINV Existing and Pipeline Drugs Customers
    14.3 Sales Channels Analysis
        14.3.1 Sales Channels
        14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
    16.1 Research Methodology
        16.1.1 Methodology/Research Approach
        16.1.2 Data Source
    16.2 Author Details
    16.3 Disclaimer

List of Tables Table 1. CINV Existing and Pipeline Drugs Market Segments Table 2. Ranking of Global Top CINV Existing and Pipeline Drugs Manufacturers by Revenue (US$ Million) in 2019 Table 3. Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type 2020-2026 (Kg) & (US$ Million) Table 4. Major Manufacturers of Aloxi (palonosetron) Table 5. Major Manufacturers of Zofran Generic (ondansetron) Table 6. Major Manufacturers of Kytril Generic (granisetron) Table 7. Major Manufacturers of Emend (aprepitant) Table 8. Major Manufacturers of Akynzeo (netupitant-palonosetron) Table 9. Major Manufacturers of SUSTOL (extended release granisetron injection) Table 10. Major Manufacturers of Rolapitant Table 11. Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application 2020-2026 (Kg) Table 12. Global CINV Existing and Pipeline Drugs Market Size by Region (Kg) & (US$ Million): 2020 VS 2026 Table 13. Global CINV Existing and Pipeline Drugs Sales by Regions 2015-2020 (Kg) Table 14. Global CINV Existing and Pipeline Drugs Sales Market Share by Regions (2015-2020) Table 15. Global CINV Existing and Pipeline Drugs Revenue by Regions 2015-2020 (US$ Million) Table 16. Global CINV Existing and Pipeline Drugs Sales Forecast by Region (2021-2026) (Kg) Table 17. Global CINV Existing and Pipeline Drugs Sales by Manufacturers (2015-2020) (Kg) Table 18. Global CINV Existing and Pipeline Drugs Sales Share by Manufacturers (2015-2020) Table 19. Global CINV Existing and Pipeline Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020) Table 20. Global CINV Existing and Pipeline Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CINV Existing and Pipeline Drugs as of 2019) Table 21. CINV Existing and Pipeline Drugs Revenue by Manufacturers (2015-2020) (US$ Million) Table 22. CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2015-2020) Table 23. Key Manufacturers CINV Existing and Pipeline Drugs Price (2015-2020) (USD/Kg) Table 24. CINV Existing and Pipeline Drugs Manufacturers Manufacturing Base Distribution and Headquarters Table 25. Manufacturers CINV Existing and Pipeline Drugs Product Type Table 26. Date of International Manufacturers Enter into CINV Existing and Pipeline Drugs Market Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans Table 28. Global CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg) Table 29. Global CINV Existing and Pipeline Drugs Sales Share by Type (2015-2020) Table 30. Global CINV Existing and Pipeline Drugs Revenue by Type (2015-2020) (US$ Million) Table 31. Global CINV Existing and Pipeline Drugs Revenue Share by Type (2015-2020) Table 32. CINV Existing and Pipeline Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Kg) Table 33. Global CINV Existing and Pipeline Drugs Sales Share by Type (2021-2026) Table 34. Global CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg) Table 35. Global CINV Existing and Pipeline Drugs Sales Share by Application (2015-2020) Table 36. Global CINV Existing and Pipeline Drugs Sales Share by Application (2021-2026) Table 37. Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Application (2021-2026) Table 38. Global CINV Existing and Pipeline Drugs Revenue by Application (2015-2020) (US$ Million) Table 39. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Application (2021-2026) Table 40. China CINV Existing and Pipeline Drugs Sales (Kg) of Key Companies (2015-2020) Table 41. China CINV Existing and Pipeline Drugs Sales Share by Company (2015-2020) Table 42. China CINV Existing and Pipeline Drugs Revenue (US$ Million) by Company (2015-2020) Table 43. China CINV Existing and Pipeline Drugs Sales (Kg) by Type (2015-2020) Table 44. China CINV Existing and Pipeline Drugs Sales Share by Type (2015-2020) Table 45. China CINV Existing and Pipeline Drugs Revenue (US$ Million) Market Share by Type (2015-2020) Table 46. China CINV Existing and Pipeline Drugs Price (Kg) by Type (2015-2020) Table 47. China CINV Existing and Pipeline Drugs Sales (Kg) by Type (2021-2026) Table 48. China CINV Existing and Pipeline Drugs Sales Share by Type (2021-2026) Table 49. China CINV Existing and Pipeline Drugs Revenue (US$ Million) Market Share by Type (2021-2026) Table 50. China CINV Existing and Pipeline Drugs Revenue Share by Type (2021-2026) Table 51. China CINV Existing and Pipeline Drugs Price (Kg) by Type (2021-2026) Table 52. China CINV Existing and Pipeline Drugs Sales (Kg) by Application (2015-2020) Table 53. China CINV Existing and Pipeline Drugs Sales Share by Application (2015-2020) Table 54. China CINV Existing and Pipeline Drugs Revenue (US$ Million) Market Share by Application (2015-2020) Table 55. China CINV Existing and Pipeline Drugs Sales (Kg) by Application (2021-2026) Table 56. China CINV Existing and Pipeline Drugs Sales Share by Application (2021-2026) Table 57. China CINV Existing and Pipeline Drugs Revenue (US$ Million) Market Share by Application (2021-2026) Table 58. China CINV Existing and Pipeline Drugs Revenue Share by Application (2021-2026) Table 59. North America CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg) Table 60. North America CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020) Table 61. North America CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million) Table 62. North America CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020) Table 63. Europe CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg) Table 64. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020) Table 65. Europe CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million) Table 66. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020) Table 67. Asia Pacific CINV Existing and Pipeline Drugs Sales by Region (2015-2020) (Kg) Table 68. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Region (2015-2020) Table 69. Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region (2015-2020) (US$ Million) Table 70. Asia Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Region (2015-2020) Table 71. Latin America CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg) Table 72. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020) Table 73. Latin Americaa CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million) Table 74. Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020) Table 75. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg) Table 76. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020) Table 77. Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million) Table 78. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020) Table 79. GlaxoSmithKline Corporation Information Table 80. GlaxoSmithKline Description and Business Overview Table 81. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 82. GlaxoSmithKline CINV Existing and Pipeline Drugs Product Table 83. GlaxoSmithKline Recent Development Table 84. Helsinn Corporation Information Table 85. Helsinn Description and Business Overview Table 86. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 87. Helsinn Product Table 88. Helsinn Recent Development Table 89. Heron Therapeutics Corporation Information Table 90. Heron Therapeutics Description and Business Overview Table 91. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 92. Heron Therapeutics Product Table 93. Heron Therapeutics Recent Development Table 94. Merck Corporation Information Table 95. Merck Description and Business Overview Table 96. Merck CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 97. Merck Product Table 98. Merck Recent Development Table 99. Tesaro Corporation Information Table 100. Tesaro Description and Business Overview Table 101. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 102. Tesaro Product Table 103. Tesaro Recent Development Table 104. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 105. Key Challenges Table 106. Market Risks Table 107. Main Points Interviewed from Key CINV Existing and Pipeline Drugs Players Table 108. CINV Existing and Pipeline Drugs Customers List Table 109. CINV Existing and Pipeline Drugs Distributors List Table 110. Research Programs/Design for This Report Table 111. Key Data Information from Secondary Sources Table 112. Key Data Information from Primary Sources List of Figures Figure 1. CINV Existing and Pipeline Drugs Product Picture Figure 2. Global CINV Existing and Pipeline Drugs Sales Market Share by Type in 2020 & 2026 Figure 3. Aloxi (palonosetron) Product Picture Figure 4. Zofran Generic (ondansetron) Product Picture Figure 5. Kytril Generic (granisetron) Product Picture Figure 6. Emend (aprepitant) Product Picture Figure 7. Akynzeo (netupitant-palonosetron) Product Picture Figure 8. SUSTOL (extended release granisetron injection) Product Picture Figure 9. Rolapitant Product Picture Figure 10. Global CINV Existing and Pipeline Drugs Sales Market Share by Application in 2020 & 2026 Figure 11. Hospitals Figure 12. Specialty Clinics Figure 13. Diagnostic Centers Therapeutics Figure 14. Hospital Pharmacies Figure 15. Drugstores Figure 16. CINV Existing and Pipeline Drugs Report Years Considered Figure 17. Global CINV Existing and Pipeline Drugs Market Size 2015-2026 (US$ Million) Figure 18. Global CINV Existing and Pipeline Drugs Sales 2015-2026 (Kg) Figure 19. Global CINV Existing and Pipeline Drugs Market Size Market Share by Region: 2020 Versus 2026 Figure 20. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2015-2020) Figure 21. Global CINV Existing and Pipeline Drugs Sales Market Share by Region in 2019 Figure 22. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2015-2020) Figure 23. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region in 2019 Figure 24. Global CINV Existing and Pipeline Drugs Sales Share by Manufacturer in 2019 Figure 25. The Top 10 and 5 Players Market Share by CINV Existing and Pipeline Drugs Revenue in 2019 Figure 26. CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 27. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020) Figure 28. Global CINV Existing and Pipeline Drugs Sales Market Share by Type in 2019 Figure 29. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2015-2020) Figure 30. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type in 2019 Figure 31. Global CINV Existing and Pipeline Drugs Market Share by Price Range (2015-2020) Figure 32. Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020) Figure 33. Global CINV Existing and Pipeline Drugs Sales Market Share by Application in 2019 Figure 34. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2015-2020) Figure 35. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application in 2019 Figure 36. China CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2026 (Kg) Figure 37. China CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2026 (US$ Million) Figure 38. China CINV Existing and Pipeline Drugs Market Share in Global Market 2015-2026 Figure 39. China 5 and 10 Largest CINV Existing and Pipeline Drugs Players Market Share by Revenue in CINV Existing and Pipeline Drugs in 2019 Figure 40. China CINV Existing and Pipeline Drugs Revenue Share by Type (2015-2020) Figure 41. China CINV Existing and Pipeline Drugs Revenue Growth Rate by Type in 2015 & 2019 Figure 42. China CINV Existing and Pipeline Drugs Revenue Share by Application (2015-2020) Figure 43. China CINV Existing and Pipeline Drugs Revenue Growth Rate by Application in 2015 & 2019 Figure 44. North America CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg) Figure 45. North America CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 46. North America CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019 Figure 47. North America CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019 Figure 48. U.S. CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 49. U.S. CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 50. Canada CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 51. Canada CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 52. Europe CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg) Figure 53. Europe CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 54. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019 Figure 55. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019 Figure 56. Germany CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 57. Germany CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 58. France CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 59. France CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. U.K. CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 61. U.K. CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Italy CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 63. Italy CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 64. Russia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 65. Russia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 66. Asia Pacific CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg) Figure 67. Asia Pacific CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 68. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Region in 2019 Figure 69. Asia Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Region in 2019 Figure 70. China CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 71. China CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. Japan CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 73. Japan CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 74. South Korea CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 75. South Korea CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. India CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 77. India CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. Australia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 79. Australia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Taiwan CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 81. Taiwan CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 82. Indonesia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 83. Indonesia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 84. Thailand CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 85. Thailand CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 86. Malaysia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 87. Malaysia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 88. Philippines CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 89. Philippines CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 90. Vietnam CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 91. Vietnam CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 92. Latin America CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg) Figure 93. Latin America CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 94. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019 Figure 95. Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019 Figure 96. Mexico CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 97. Mexico CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 98. Brazil CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 99. Brazil CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 100. Argentina CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 101. Argentina CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 102. Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg) Figure 103. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million) Figure 104. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019 Figure 105. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019 Figure 106. Turkey CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 107. Turkey CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 108. Saudi Arabia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 109. Saudi Arabia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 110. U.A.E CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg) Figure 111. U.A.E CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 112. Porter's Five Forces Analysis Figure 113. CINV Existing and Pipeline Drugs Value Chain Figure 114. Channels of Distribution Figure 115. Distributors Profiles Figure 116. Bottom-up and Top-down Approaches for This Report Figure 117. Data Triangulation Figure 118. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us